Meropenem
‘Likely clinically important benefit’ with continuous beta-lactam antibiotic infusions
More ICU patients with sepsis receiving a continuous vs. intermittent infusion of beta-lactam antibiotics achieved clinical cure by day 14, but 90-day mortality was similar, according to research published in JAMA.
Cefepime-taniborbactam statistically superior to meropenem for treatment of cUTI
WASHINGTON — Cefepime-taniborbactam was statistically superior to meropenem for the treatment of complicated UTIs, including acute pyelonephritis, according to data presented at IDWeek.
‘We are learning from this’: After death of FMT recipient, a warning about screening
Cefiderocol noninferior to high-dose meropenem in phase 3 trial for nosocomial pneumonia
WASHINGTON — Cefiderocol, a novel siderophore cephalosporin, was noninferior to high-dose meropenem for the primary endpoint of all-cause mortality 14 days after treatment was started in patients with nosocomial pneumonia caused by gram-negative pathogens, according to results of a randomized phase 3 trial called APEKS-NP.
Novel drug combination noninferior to meropenem for treating cUTIs
A novel combination that includes ceftriaxone, sulbactam and disodium EDTA, or CSE, was noninferior to meropenem for the treatment of complicated UTIs, or cUTIs, caused by extended-spectrum beta-lactamase-producing, or ESBL-producing, gram-negative bacteria, according to results from the phase 3 PLEA trial.